Mechanism of Action of Baxfendy (Baxdrostat)
Baxdrostat is a highly selective aldosterone synthase (CYP11B2) inhibitor that lowers blood pressure by directly blocking aldosterone production in the adrenal glands, thereby reducing sodium and water retention without suppressing cortisol synthesis. 1
How It Works
Baxdrostat targets the final enzymatic step in aldosterone biosynthesis by inhibiting CYP11B2 (aldosterone synthase). This mechanism differs fundamentally from mineralocorticoid receptor antagonists (MRAs) like spironolactone, which block aldosterone's effects at the receptor level but don't reduce aldosterone production itself 1.
Key Mechanistic Features:
Selective enzyme inhibition: Baxdrostat demonstrates substantially higher potency and selectivity for aldosterone synthase (CYP11B2) compared to the closely related enzyme 11β-hydroxylase (CYP11B1), which is responsible for cortisol synthesis 1
Preserved cortisol axis: In both nonclinical and clinical studies, baxdrostat significantly lowered aldosterone concentrations across a wide dose range without affecting cortisol responses or ACTH-stimulated cortisol secretion—even at doses up to 180 times the maximum recommended dose 1, 1
No sex hormone effects: Unlike some steroidogenesis inhibitors, baxdrostat does not inhibit synthesis of sex hormones such as testosterone and estrone 1
Pharmacodynamic Effects
Aldosterone suppression: At therapeutic doses (1-2 mg), baxdrostat produces sustained, dose-dependent decreases in plasma aldosterone concentrations:
- Up to 70-83% reduction in plasma aldosterone after initial dosing 1
- Sustained 68-73% reduction maintained at Day 10 1
- Decreased 24-hour urinary aldosterone excretion observed up to 32 weeks 1
Compensatory renin response: As expected with aldosterone reduction, plasma renin activity increases—a physiologic feedback response 1
Clinical Relevance of Selectivity
The 2024 ESC Guidelines acknowledge baxdrostat as a novel aldosterone synthase inhibitor that has significantly lowered blood pressure in phase 2 trials of patients with uncontrolled hypertension 2. The guidelines also note its potential role in primary aldosteronism, where newer agents like baxdrostat are being tested alongside traditional MRAs 2.
The critical advantage of CYP11B2 selectivity is the avoidance of cortisol suppression and associated adrenal insufficiency risks seen with non-selective inhibitors. Research confirms baxdrostat shows stronger predicted binding to CYP11B2 (-11.5 kcal/mol) with limited engagement of CYP11B1, resulting in minimal cortisol axis impact and smaller upstream steroid precursor accumulation compared to less selective agents 3.
Downstream Effects on Blood Pressure
By reducing aldosterone levels, baxdrostat:
- Decreases renal sodium and water retention, reducing blood volume 1
- Mitigates aldosterone-mediated vascular dysfunction, inflammation, and fibrosis 1
- Provides blood pressure reduction through a mechanistically distinct pathway from traditional antihypertensives 2
This aldosterone-targeted mechanism makes baxdrostat particularly relevant for resistant hypertension, where aldosterone excess often drives treatment resistance despite multidrug therapy 2, 2.